← Multiple Sclerosis and Demyelinating Disorders
Papers in Multiple Sclerosis and Demyelinating Disorders
Page 1 · newest first
- GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patientsMultiple Sclerosis and Demyelinating Disorders · 2019
- Quality of life differences between African Americans and Hispanic Americans with multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2019
- Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectivesMultiple Sclerosis and Demyelinating Disorders · 2018
- Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologistsMultiple Sclerosis and Demyelinating Disorders · 2018
- Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorderMultiple Sclerosis and Demyelinating Disorders · 2018
- The role of puberty and adolescence in the pathobiology of pediatric multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2018
- Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2018
- Differentiating Vogt-Koyanagi-Harada syndrome from recurrent optic neuritis: a case report and review of the literature concerning Hispanic patientsMultiple Sclerosis and Demyelinating Disorders · 2017
- The economic profile of peginterferon beta-1a in the treatment of relapsing-remitting multiple sclerosis in ItalyMultiple Sclerosis and Demyelinating Disorders · 2017
- Cardiovascular comorbidity in multiple sclerosis patients treated with Mitoxantrone therapy: a cohort studyMultiple Sclerosis and Demyelinating Disorders · 2017
- Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2017
- May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective studyMultiple Sclerosis and Demyelinating Disorders · 2017
- Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?Multiple Sclerosis and Demyelinating Disorders · 2017
- Alemtuzumab for multiple sclerosis: the new concept of immunomodulationMultiple Sclerosis and Demyelinating Disorders · 2017
- Coincident onset of multiple sclerosis and Herpes simplex virus 1 encephalitis: a case reportMultiple Sclerosis and Demyelinating Disorders · 2017
- Pediatric versus adult MS: similar or different?Multiple Sclerosis and Demyelinating Disorders · 2017
- Myelin-derived and putative molecular mimic peptides share structural properties in aqueous and membrane-like environmentsMultiple Sclerosis and Demyelinating Disorders · 2017
- Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiationMultiple Sclerosis and Demyelinating Disorders · 2017
- Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2017
- The still under-investigated role of cognitive deficits in PML diagnosisMultiple Sclerosis and Demyelinating Disorders · 2017
- Cytokine profiles in pediatric multiple sclerosisView · 2016
- Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observationMultiple Sclerosis and Demyelinating Disorders · 2016
- Epidemiology of MS in Russia, a historical reviewMultiple Sclerosis and Demyelinating Disorders · 2016
- The link of inflammation and neurodegeneration in progressive multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
- The heritage of glatiramer acetate and its use in multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
- Antibodies in acquired demyelinating disorders in childrenMultiple Sclerosis and Demyelinating Disorders · 2016
- Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosisMultiple Sclerosis and Demyelinating Disorders · 2016
- Neuroprotective therapies for multiple sclerosis and other demyelinating diseasesMultiple Sclerosis and Demyelinating Disorders · 2016